Literature DB >> 36262946

Li-Fraumeni Syndrome: A Rare Genetic Disorder.

Faria Tazin1, Harendra Kumar2, Muhammad A Israr3, Deborah Omoleye4, Vern Orlang1.   

Abstract

Li-Fraumeni syndrome (LFS) is an inherited genetic condition that makes individuals predisposed to specific types of cancer. As a result, cancer risk can be passed down from generation to generation. TP53 is the genetic blueprint for a protein called p53 and most commonly causes this condition by mutations or alterations in that gene. Mutations prevent the gene from functioning properly. LFS is associated with TP53 gene mutations in approximately 70% of families. Most patients with LFS have one normal copy of TP53 and one mutated copy of TP53, usually inherited from a parent with the condition. This is a case report of a 40-year-old female who underwent genetic testing to determine her p53 mutation status. Her mother was diagnosed with breast cancer at a young age, despite the fact that her brothers and sisters' genetic tests came out normal. The genetic testing showed her as a carrier for the TP53 gene mutation. Despite the fact that she had no signs or symptoms of any linked tumors associated with the condition, she was diagnosed with LFS.
Copyright © 2022, Tazin et al.

Entities:  

Keywords:  cancer; family medicine; hereditary diseases; internal medicine; le fraumeni syndrome

Year:  2022        PMID: 36262946      PMCID: PMC9573781          DOI: 10.7759/cureus.29240

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

1.  A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.

Authors:  J M Varley; M Thorncroft; G McGown; J Appleby; A M Kelsey; K J Tricker; D G Evans; J M Birch
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

Authors:  Jana Hof; Stefanie Krentz; Claudia van Schewick; Gabriele Körner; Shabnam Shalapour; Peter Rhein; Leonid Karawajew; Wolf-Dieter Ludwig; Karl Seeger; Günter Henze; Arend von Stackelberg; Christian Hagemeier; Cornelia Eckert; Renate Kirschner-Schwabe
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

3.  Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

Authors:  T Frebourg; J Kassel; K T Lam; M A Gryka; N Barbier; T I Andersen; A L Børresen; S H Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

4.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  S Srivastava; Z Q Zou; K Pirollo; W Blattner; E H Chang
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

Review 5.  Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Authors:  Bernard Leroy; Mandy L Ballinger; Fanny Baran-Marszak; Gareth L Bond; Antony Braithwaite; Nicole Concin; Lawrence A Donehower; Wafik S El-Deiry; Pierre Fenaux; Gianluca Gaidano; Anita Langerød; Eva Hellstrom-Lindberg; Richard Iggo; Jacqueline Lehmann-Che; Phuong L Mai; David Malkin; Ute M Moll; Jeffrey N Myers; Kim E Nichols; Sarka Pospisilova; Patricia Ashton-Prolla; Davide Rossi; Sharon A Savage; Louise C Strong; Patricia N Tonin; Robert Zeillinger; Thorsten Zenz; Joseph F Fraumeni; Peter E M Taschner; Pierre Hainaut; Thierry Soussi
Journal:  Cancer Res       Date:  2017-03-15       Impact factor: 12.701

6.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

7.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Authors:  Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 9.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

10.  Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.

Authors:  Christian P Kratz; Claire Freycon; Kara N Maxwell; Kim E Nichols; Joshua D Schiffman; D Gareth Evans; Maria I Achatz; Sharon A Savage; Jeffrey N Weitzel; Judy E Garber; Pierre Hainaut; David Malkin
Journal:  JAMA Oncol       Date:  2021-12-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.